Sunshine Biopharma director granted 100,000 shares

NATAN DAVID reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

NATAN DAVID reported acquisition or exercise transactions in this Form 4 filing.

Sunshine Biopharma Inc. director Natan David received a stock award of 100,000 shares of Common Stock. The shares were granted at a price of $0.00 per share as compensation, not through an open-market purchase. Following this grant, he directly holds 100,000 shares.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider NATAN DAVID

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	100,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 100,000 shares (Direct)

Footnotes (1)

1. F1. Represents a stock award to the reporting person.

Key Figures

Stock award size: 100,000 shares Award price per share: $0.00 per share Shares held after transaction: 100,000 shares

3 metrics

Stock award size 100,000 shares Common Stock granted to director Natan David

Award price per share $0.00 per share Grant/award acquisition, non-market transaction

Shares held after transaction 100,000 shares Direct holdings following the stock award

Key Terms

stock award, grant/award acquisition, Common Stock, Form 4

4 terms

stock award financial

"Represents a stock award to the reporting person."

grant/award acquisition financial

"transaction_action: "grant/award acquisition" describing the share grant."

Common Stock financial

"security_title: "Common Stock" for the shares awarded."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4) for Sunshine Biopharma Inc."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sunshine Biopharma (SBFM) report for Natan David?

Sunshine Biopharma reported that director Natan David received a stock award of 100,000 Common Stock shares. The award was classified as a grant or other acquisition and did not involve an open-market purchase or sale of shares.

Was the Sunshine Biopharma (SBFM) Form 4 transaction a buy or a sale?

The Form 4 transaction for Sunshine Biopharma director Natan David was an acquisition via stock award, not a market buy or sale. It reflects compensation granted in shares, rather than a trade executed on the open market.

How many Sunshine Biopharma (SBFM) shares does Natan David hold after this award?

After the reported transaction, director Natan David directly holds 100,000 shares of Sunshine Biopharma Common Stock. All of these shares come from the most recent stock award reported in the Form 4 filing.

What was the price per share for Natan David’s Sunshine Biopharma stock award?

The reported price per share for Natan David’s Sunshine Biopharma stock award was $0.00. This indicates the shares were granted as compensation rather than purchased for cash in the open market.

How is the Sunshine Biopharma (SBFM) Form 4 transaction classified by the SEC codes?

The Sunshine Biopharma transaction is coded "A", described as a grant, award, or other acquisition of Common Stock. The filing labels the direction as an acquisition and confirms it is a non-derivative, compensation-related stock award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/14/2026 - 04:26 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NATAN DAVID

(Last) (First) (Middle)

C/O SUNSHINE BIOPHARMA, INC.

333 LAS OLAS WAY, CU4 SUITE 433

(Street)

FORT LAUDERDALE FLORIDA 33301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sunshine Biopharma Inc. [ SBFM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/14/2026		A(1)		100,000	A	$0	100,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a stock award to the reporting person.

	/s/ David Natan	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)